SARS-CoV-2 Vaccination and Chilblain-like Lesions: What Do We Know So Far?
Keywords:
COVID-19, COVID-19 Vaccine, Chilblain-like Lesions, Pernio-like Lesions, Post COVID-19 VaccinationAbstract
The coronavirus pandemic has caused massive damage to global health care and the economy. COVID-19 vaccination and following the government protocols is the only way to tackle this situation. The vaccination program has been paced around the globe to return as soon as possible to pre-COVID time. Although all the vaccines have been approved after the rigorous clinical and safety trials, some adverse effects have surfaced and are being reported from different parts of the world. One such side effect is chilblain-like lesions following the COVID vaccination. Chilblain lesions, also known as pernio, are an inflammatory condition usually affecting the acral regions of the body. It is mostly reported from cold and damp areas and has multiple causes associated with it. Reporting of such similar lesions has raised concern amongst the scientific community and has led to vaccine hesitancy amongst the general population. The exact mechanism behind these lesions is still unknown. Although the incidence of this condition is low, it still requires attention from the authorities. This study aims to review the publicly available data and to provide concise and comprehensive information on chilblain-like lesions post-COVID-vaccination.
References
1. C H, Y W, X L, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London, England). 2020;395(10223):497-506. doi:10.1016/S0140-6736(20)30183-5
2. Y H, H Y. The transmission and diagnosis of 2019 novel coronavirus infection disease (COVID-19): A Chinese perspective. Journal of medical virology. 2020;92(6):639-644. doi:10.1002/JMV.25749
3. LA V, G S, G D, G DR. Anosmia and Ageusia: Common Findings in COVID-19 Patients. The Laryngoscope. 2020;130(7):1787. doi:10.1002/LARY.28692
4. D H, B L, N S, S R, WV K, D W. Anosmia in COVID-19 patients. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2020;26(10):1426-1427. doi:10.1016/J.CMI.2020.05.017
5. Esakandari H, Nabi-Afjadi M, Fakkari-Afjadi J, Farahmandian N, Miresmaeili SM, Bahreini E. A comprehensive review of COVID-19 characteristics. Biological Procedures Online 2020 22:1. 2020;22(1):1-10. doi:10.1186/S12575-020-00128-2
6. A G, MV M, K S, et al. Extrapulmonary manifestations of COVID-19. Nature medicine. 2020;26(7):1017-1032. doi:10.1038/S41591-020-0968-3
7. Sachdeva M, Gianotti R, Shah M, et al. Cutaneous manifestations of COVID-19: Report of three cases and a review of literature. Journal of Dermatological Science. 2020;98(2):75. doi:10.1016/J.JDERMSCI.2020.04.011
8. ZP Y, M Y, CL L. COVID-19 Vaccines: A Review of the Safety and Efficacy of Current Clinical Trials. Pharmaceuticals (Basel, Switzerland). 2021;14(5). doi:10.3390/PH14050406
9. AF H, D C, K P, AO D, AM T. Safety of COVID-19 vaccines administered in the EU: Should we be concerned? Toxicology reports. 2021;8:871-879. doi:10.1016/J.TOXREP.2021.04.003
10. Urban N, Weber B, Deinsberger J, Gschwandtner M, Bauer W, Handisurya A. Raynaud’s Phenomenon after COVID-19 Vaccination: Causative Association, Temporal Connection, or Mere Bystander? Case Reports in Dermatology. 2021;13:450-456. doi:10.1159/000519147
11. Ahmed SH, Shaikh TG, Waseem S, Qadir NA, Yousaf Z, Ullah I. Vaccine-induced thrombotic thrombocytopenia following coronavirus vaccine: A narrative review. Annals of Medicine and Surgery. Published online October 30, 2021:102988. doi:10.1016/J.AMSU.2021.102988
12. RL W, L S, A K, I A, J R. COVID-19 Vaccine To Vaccination: Why Leaders Must Invest In Delivery Strategies Now. Health affairs (Project Hope). 2021;40(1):33-41. doi:10.1377/HLTHAFF.2020.01523
13. Massey PR, Jones KM. Going viral: A brief history of Chilblain-like skin lesions (“COVID toes”) amidst the COVID-19 pandemic. Seminars in Oncology. 2020;47(5):330. doi:10.1053/J.SEMINONCOL.2020.05.012
14. JA C, DA W. Clinical characteristics, etiologic associations, laboratory findings, treatment, and proposal of diagnostic criteria of pernio (chilblains) in a series of 104 patients at Mayo Clinic, 2000 to 2011. Mayo Clinic proceedings. 2014;89(2):207-215. doi:10.1016/J.MAYOCP.2013.09.020
15. Nyssen A, Benhadou F, Magnée M, André J, Koopmansch C, Wautrecht JC. Chilblains. https://doi.org/101024/0301-1526/a000838. 2019;49(2):133-140. doi:10.1024/0301-1526/A000838
16. C GC, A C, G CH, et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. The British journal of dermatology. 2020;183(1):71-77. doi:10.1111/BJD.19163
17. JD B, TA D, M J, et al. Vascular skin symptoms in COVID-19: a French observational study. Journal of the European Academy of Dermatology and Venereology : JEADV. 2020;34(9):e451-e452. doi:10.1111/JDV.16544
18. V P, I N, C F, et al. Chilblain-like lesions during COVID-19 epidemic: a preliminary study on 63 patients. Journal of the European Academy of Dermatology and Venereology : JEADV. 2020;34(7):e291-e293. doi:10.1111/JDV.16526
19. S R, T B, LA F, et al. Acral cutaneous lesions in the time of COVID-19. Journal of the European Academy of Dermatology and Venereology : JEADV. 2020;34(8):e346-e347. doi:10.1111/JDV.16533
20. PR M, KM J. Going viral: A brief history of Chilblain-like skin lesions (“COVID toes”) amidst the COVID-19 pandemic. Seminars in oncology. 2020;47(5):330-334. doi:10.1053/J.SEMINONCOL.2020.05.012
21. L LC, L D, H A, et al. Most chilblains observed during the COVID-19 outbreak occur in patients who are negative for COVID-19 on polymerase chain reaction and serology testing. The British journal of dermatology. 2020;183(5):866-874. doi:10.1111/BJD.19377
22. Piccolo V, Bassi A, Russo T, et al. Chilblain‐like lesions and COVID‐19: second wave, second outbreak. Journal of the European Academy of Dermatology and Venereology. 2021;35(5):e316-e318. doi:10.1111/JDV.17145
23. M B, A H. COVID toes: where do we stand with the current evidence? International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2021;102:53-55. doi:10.1016/J.IJID.2020.10.021
24. C L, J K, A V, et al. COVID-19 and outbreak of chilblains: are they related? Journal of the European Academy of Dermatology and Venereology : JEADV. 2020;34(12):e757-e758. doi:10.1111/JDV.16779
25. Mascellino MT, Timoteo F di, Angelis M de, Oliva A. Overview of the Main Anti-SARS-CoV-2 Vaccines: Mechanism of Action, Efficacy and Safety. Infection and Drug Resistance. 2021;14:3459. doi:10.2147/IDR.S315727
26. Do MH, Stewart CR, Harp J. Cutaneous Manifestations of COVID-19 in the Inpatient Setting. Dermatologic Clinics. 2021;39(4):521-532. doi:10.1016/J.DET.2021.05.011
27. N C, M S, M M, SP N, A C. Pernio-like skin lesions after the second dose of Pfizer-BioNTech COVID-19 vaccine. Journal of the European Academy of Dermatology and Venereology : JEADV. 2021;35(11). doi:10.1111/JDV.17500
28. Cappel MA, Cappel JA, Wetter DA. Pernio (Chilblains), SARS-CoV-2, and COVID Toes Unified Through Cutaneous and Systemic Mechanisms. Mayo Clinic Proceedings. 2021;96(4):989-1005. doi:10.1016/J.MAYOCP.2021.01.009
29. Verdecchia P, Cavallini C, Spanevello A, Angeli F. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. European Journal of Internal Medicine. 2020;76:14. doi:10.1016/J.EJIM.2020.04.037
30. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines — a new era in vaccinology. Nature reviews Drug discovery. 2018;17(4):261. doi:10.1038/NRD.2017.243
31. JR T, DL F. COVID-19 vaccines: modes of immune activation and future challenges. Nature reviews Immunology. 2021;21(4):195-197. doi:10.1038/S41577-021-00526-X
32. MA L, N L, C C, K N, ML R. Approach to Chilblains During the COVID-19 Pandemic [Formula: see text]. Journal of cutaneous medicine and surgery. 2020;24(5):504-517. doi:10.1177/1203475420937978
33. (10) (PDF) Cytokine Storm Response to COVID-19 Vaccinations. Accessed October 16, 2021. https://www.researchgate.net/publication/349257945_Cytokine_Storm_Response_to_COVID-19_Vaccinations
34. Mahase E. Covid-19: UK government asks regulator to assess Oxford vaccine as questions are raised over interim data. BMJ. 2020;371:m4670. doi:10.1136/BMJ.M4670
35. Ragab D, Eldin HS, Taeimah M, Khattab R, Salem R. The COVID-19 Cytokine Storm; What We Know So Far. Frontiers in Immunology. 2020;11. doi:10.3389/FIMMU.2020.01446
36. Lesort C, Kanitakis J, Donzier L, Jullien D. Chilblain-like lesions after BNT162b2 mRNA COVID-19 vaccine: a case report suggesting that ‘COVID toes’ are due to the immune reaction to SARS-CoV-2. Journal of the European Academy of Dermatology and Venereology. 2021;35(10):e630-e632. doi:10.1111/JDV.17451
37. GA H, M D, B L, et al. A case series of cutaneous COVID-19 vaccine reactions at Loma Linda University Department of Dermatology. JAAD case reports. 2021;16:53-57. doi:10.1016/J.JDCR.2021.07.038
38. Meara AS, Silkoski M, Quin K, Jarjour W. A Case of Chilblains-like Lesions Post SARS-CoV-2 Vaccine? The Journal of Rheumatology. 2021;(1):jrheum.210226. doi:10.3899/JRHEUM.210226
39. Lopez S, Vakharia P, Vandergriff T, Freeman EE, Vasquez R. Pernio after COVID-19 vaccination. British Journal of Dermatology. 2021;185(2):445-447. doi:10.1111/BJD.20404
40. Kha C, Itkin A. New-onset chilblains in close temporal association to mRNA-1273 vaccination. JAAD Case Reports. 2021;12:12-14. doi:10.1016/J.JDCR.2021.03.046
41. A B, I B, MT FF, C F. Perniosis: clinical and histopathological analysis. The American Journal of dermatopathology. 2010;32(1):19-23. doi:10.1097/DAD.0B013E3181AF1D24
42. Cribier B, Djeridi N, Peltre B, Grosshans E. A histologic and immunohistochemical study of chilblains. Journal of the American Academy of Dermatology. 2001;45(6):924-929. doi:10.1067/MJD.2001.117861
43. C GC, A C, G CH, et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. The British journal of dermatology. 2020;183(1):71-77. doi:10.1111/BJD.19163
44. Whitman PA, Crane JS. Pernio. Current Treatment Options in Cardiovascular Medicine. 2021;10(2):128-135. Accessed October 15, 2021. https://www.ncbi.nlm.nih.gov/books/NBK549842/
45. Temiz SA, Abdelmaksoud A, Dursun R, Vestita M. Acral chilblain-like lesions following inactivated SARS-CoV-2 vaccination. International Journal of Dermatology. 2021;60(9):1152-1153. doi:10.1111/IJD.15619
46. Piccolo V, Bassi A, Argenziano G, et al. Dermoscopy of chilblain-like lesions during the COVID-19 outbreak: A multicenter study on 10 patients. Journal of the American Academy of Dermatology. 2020;83(6):1749. doi:10.1016/J.JAAD.2020.07.058
47. Chilblain-Like Lesions in COVID-19: A Detailed Review. Accessed October 15, 2021. https://www.fortunejournals.com/articles/chilblainlike-lesions-in-covid19-a-detailed-review.html
48. M P, F M, MG K. Pharmacologic Treatment of Idiopathic Chilblains (Pernio): A Systematic Review. Journal of cutaneous medicine and surgery. 2021;25(5):530-542. doi:10.1177/1203475421995130
49. A A, DS P. Pernio (chilblains). Current treatment options in cardiovascular medicine. 2008;10(2):128-135. doi:10.1007/S11936-008-0014-0
50. M K, B I, S M, M A. Cutaneous and histopathological features of coronavirus disease 2019 in pediatrics: A review article. Dermatologic therapy. 2021;34(1). doi:10.1111/DTH.14554
51. Discepolo V, Catzola A, Pierri L, et al. Bilateral Chilblain-like Lesions of the Toes Characterized by Microvascular Remodeling in Adolescents During the COVID-19 Pandemic. JAMA Network Open. 2021;4(6):e2111369-e2111369. doi:10.1001/JAMANETWORKOPEN.2021.11369
52. Vano-Galvan S, Martorell A. Chilblains. CMAJ. 2012;184(1):67-67. doi:10.1503/CMAJ.110100
53. IH S, JH B, P S, AL LJ. Assessing the effectiveness of topical betamethasone to treat chronic chilblains: a randomised clinical trial in primary care. The British journal of general practice : the journal of the Royal College of General Practitioners. 2017;67(656):e187-e193. doi:10.3399/BJGP17X689413
54. Chou R, Dana T. Screening Adults for Bladder Cancer. Screening Adults for Bladder Cancer: Update of the 2004 Evidence Review for the US Preventive Services Task Force. Published online 2010. Accessed October 15, 2021. https://www.ncbi.nlm.nih.gov/books/NBK47510/
55. Khalid T, Arif Maan M, Shehzad K. Comparison of efficacy and safety of topical glyceryl trinitrate vs. oral nifedipine in idiopathic perniosis: results of a randomized clinical trial. Journal of Pakistan Association of Dermatologists. 2014;24(4):342-347.
56. Jain AK, K.R R, Margaankar M. A random comparative therapeutic trial of oral nifedipine v/s topical 5% minoxidil gel in patients of perniosis at a tertiary care center of North-western India. IP Indian Journal of Clinical and Experimental Dermatology. 2020;4(1):62-65. doi:10.18231/.2018.0014
57. Alkubaisi TA, Salih Hasan A. Treatment of Perniosis with Oral Nifedipine in Comparison with Topical 5% Minoxidil Solution in Iraqi Patients. Single Blind Comparative Study. Published online 2010. Accessed October 16, 2021. https://www.researchgate.net/publication/340129930
58. Diltiazem vs. nifedipine in chilblains: a clinical trial - PubMed. Accessed October 15, 2021. https://pubmed.ncbi.nlm.nih.gov/17642888/
59. IH S, JH B, P S, AL LJ. Nifedipine vs Placebo for Treatment of Chronic Chilblains: A Randomized Controlled Trial. Annals of family medicine. 2016;14(5):453-459. doi:10.1370/AFM.1966
60. Molecular mechanism of cGMP-mediated smooth muscle relaxation - PubMed. Accessed October 15, 2021. https://pubmed.ncbi.nlm.nih.gov/10911373/
61. Topical Nitroglycerine in Perniosis/Chilblains - PubMed. Accessed October 15, 2021. https://pubmed.ncbi.nlm.nih.gov/26380502/
62. Weingarten M, Abittan B, Rivera-Oyola R, Abittan AI, Weingarten M, Lebwohl M. Treatment of COVID-19 induced chilblains with topical nitroglycerin. International Journal of Dermatology. 2020;59(12):1522-1524. doi:10.1111/IJD.15253
63. Annamaraju P, Baradhi KM. Pentoxifylline. xPharm: The Comprehensive Pharmacology Reference. Published online August 22, 2021:1-18. Accessed October 15, 2021. https://www.ncbi.nlm.nih.gov/books/NBK559096/
64. Treatment of perniosis with oral pentoxyfylline in comparison with oral prednisolone plus topical clobetasol ointment in Iraqi patients - PubMed. Accessed October 15, 2021. https://pubmed.ncbi.nlm.nih.gov/19082229/
65. NK AS. Treatment of primary perniosis with oral pentoxifylline (a double-blind placebo-controlled randomized therapeutic trial). Dermatologic therapy. 2016;29(4):263-268. doi:10.1111/DTH.12350
66. Rich R, Fleisher T, Shearer W, Schroeder H, Frew A, Weyand C. Clinical Immunology - Principles and Practice. Published online 2008:1530.
67. Successful treatment of perniosis with hydroxychloroquine - PubMed. Accessed October 15, 2021. https://pubmed.ncbi.nlm.nih.gov/20941949/
68. RI F. Mechanism of action of hydroxychloroquine as an antirheumatic drug. Seminars in arthritis and rheumatism. 1993;23(2 Suppl 1):82-91. doi:10.1016/S0049-0172(10)80012-5
69. [Clinical observation on 136 cases of chilblains treated by acupuncture combined with massage] - PubMed. Accessed October 15, 2021. https://pubmed.ncbi.nlm.nih.gov/16312923/
70. LR B, HM ES, B E, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. The New England journal of medicine. 2021;384(5):403-416. doi:10.1056/NEJMOA2035389
71. Mazzatenta C, Piccolo V, Pace G, Romano I, Argenziano G, Bassi A. Purpuric lesions on the eyelids developed after BNT162b2 mRNA COVID‐19 vaccine: another piece of SARS‐CoV‐2 skin puzzle? Journal of the European Academy of Dermatology and Venereology. 2021;35(9):e543-e545. doi:10.1111/JDV.17340
72. M C, A D, MR V, et al. Transient cutaneous manifestations after administration of Pfizer-BioNTech COVID-19 Vaccine: an Italian single-centre case series. Journal of the European Academy of Dermatology and Venereology : JEADV. 2021;35(8):e483-e485. doi:10.1111/JDV.17268
73. M A, D H, A F, R B, E E. Persistent maculopapular rash after the first dose of Pfizer-BioNTech COVID-19 vaccine. Journal of the European Academy of Dermatology and Venereology : JEADV. 2021;35(7):e423-e425. doi:10.1111/JDV.17248
74. Morbilliform rash after administration of Pfizer-BioNTech COVID-19 mRNA vaccine - PubMed. Accessed November 6, 2021. https://pubmed.ncbi.nlm.nih.gov/33560802/
75. HJ P, JR M, NA B. Anaphylaxis After the Covid-19 Vaccine in a Patient With Cholinergic Urticaria. Military medicine. Published online April 14, 2021. doi:10.1093/MILMED/USAB138
76. DE M, E A, M R, et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases. Journal of the American Academy of Dermatology. 2021;85(1):46-55. doi:10.1016/J.JAAD.2021.03.092
77. JM BL, G SN, A MI, et al. Pityriasis rosea, COVID-19 and vaccination: new keys to understand an old acquaintance. Journal of the European Academy of Dermatology and Venereology : JEADV. 2021;35(8):e489-e491. doi:10.1111/JDV.17301
78. V P, C M, A B, et al. COVID vaccine-induced lichen planus on areas previously affected by vitiligo. Journal of the European Academy of Dermatology and Venereology : JEADV. Published online 2021. doi:10.1111/JDV.17687
79. B D, H M, M FB, K J, P de T. “Blue toes” following vaccination with the BNT162b2 mRNA COVID-19 vaccine. Journal of travel medicine. 2021;28(4). doi:10.1093/JTM/TAAB024
80. Piccolo V, Bassi A, Argenziano G, et al. BNT162b2 mRNA COVID-19 vaccine-induced chilblain-like lesions reinforces the hypothesis of their relationship with SARS-CoV-2. Journal of the European Academy of Dermatology and Venereology. 2021;35(8):e493-e494. doi:10.1111/JDV.17320
81. Pileri A, Guglielmo A, Raone B, Patrizi A. Chilblain lesions after COVID-19 mRNA vaccine. British Journal of Dermatology. 2021;185(1):e3-e3. doi:10.1111/BJD.20060
82. Revilla-Nebreda D, Roncero-Riesco M, Santos-Briz Á, Medina-Migueláñez M, Segurado-Tostón N, Román-Curto C. New-onset acral lesions on hands after administration of mRNA-1273 vaccine against SARS-CoV-2: clinical images and histopathological study of three cases. Journal of the European Academy of Dermatology and Venereology. 2021;35(11):e747-e749. doi:10.1111/JDV.17553
2. Y H, H Y. The transmission and diagnosis of 2019 novel coronavirus infection disease (COVID-19): A Chinese perspective. Journal of medical virology. 2020;92(6):639-644. doi:10.1002/JMV.25749
3. LA V, G S, G D, G DR. Anosmia and Ageusia: Common Findings in COVID-19 Patients. The Laryngoscope. 2020;130(7):1787. doi:10.1002/LARY.28692
4. D H, B L, N S, S R, WV K, D W. Anosmia in COVID-19 patients. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2020;26(10):1426-1427. doi:10.1016/J.CMI.2020.05.017
5. Esakandari H, Nabi-Afjadi M, Fakkari-Afjadi J, Farahmandian N, Miresmaeili SM, Bahreini E. A comprehensive review of COVID-19 characteristics. Biological Procedures Online 2020 22:1. 2020;22(1):1-10. doi:10.1186/S12575-020-00128-2
6. A G, MV M, K S, et al. Extrapulmonary manifestations of COVID-19. Nature medicine. 2020;26(7):1017-1032. doi:10.1038/S41591-020-0968-3
7. Sachdeva M, Gianotti R, Shah M, et al. Cutaneous manifestations of COVID-19: Report of three cases and a review of literature. Journal of Dermatological Science. 2020;98(2):75. doi:10.1016/J.JDERMSCI.2020.04.011
8. ZP Y, M Y, CL L. COVID-19 Vaccines: A Review of the Safety and Efficacy of Current Clinical Trials. Pharmaceuticals (Basel, Switzerland). 2021;14(5). doi:10.3390/PH14050406
9. AF H, D C, K P, AO D, AM T. Safety of COVID-19 vaccines administered in the EU: Should we be concerned? Toxicology reports. 2021;8:871-879. doi:10.1016/J.TOXREP.2021.04.003
10. Urban N, Weber B, Deinsberger J, Gschwandtner M, Bauer W, Handisurya A. Raynaud’s Phenomenon after COVID-19 Vaccination: Causative Association, Temporal Connection, or Mere Bystander? Case Reports in Dermatology. 2021;13:450-456. doi:10.1159/000519147
11. Ahmed SH, Shaikh TG, Waseem S, Qadir NA, Yousaf Z, Ullah I. Vaccine-induced thrombotic thrombocytopenia following coronavirus vaccine: A narrative review. Annals of Medicine and Surgery. Published online October 30, 2021:102988. doi:10.1016/J.AMSU.2021.102988
12. RL W, L S, A K, I A, J R. COVID-19 Vaccine To Vaccination: Why Leaders Must Invest In Delivery Strategies Now. Health affairs (Project Hope). 2021;40(1):33-41. doi:10.1377/HLTHAFF.2020.01523
13. Massey PR, Jones KM. Going viral: A brief history of Chilblain-like skin lesions (“COVID toes”) amidst the COVID-19 pandemic. Seminars in Oncology. 2020;47(5):330. doi:10.1053/J.SEMINONCOL.2020.05.012
14. JA C, DA W. Clinical characteristics, etiologic associations, laboratory findings, treatment, and proposal of diagnostic criteria of pernio (chilblains) in a series of 104 patients at Mayo Clinic, 2000 to 2011. Mayo Clinic proceedings. 2014;89(2):207-215. doi:10.1016/J.MAYOCP.2013.09.020
15. Nyssen A, Benhadou F, Magnée M, André J, Koopmansch C, Wautrecht JC. Chilblains. https://doi.org/101024/0301-1526/a000838. 2019;49(2):133-140. doi:10.1024/0301-1526/A000838
16. C GC, A C, G CH, et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. The British journal of dermatology. 2020;183(1):71-77. doi:10.1111/BJD.19163
17. JD B, TA D, M J, et al. Vascular skin symptoms in COVID-19: a French observational study. Journal of the European Academy of Dermatology and Venereology : JEADV. 2020;34(9):e451-e452. doi:10.1111/JDV.16544
18. V P, I N, C F, et al. Chilblain-like lesions during COVID-19 epidemic: a preliminary study on 63 patients. Journal of the European Academy of Dermatology and Venereology : JEADV. 2020;34(7):e291-e293. doi:10.1111/JDV.16526
19. S R, T B, LA F, et al. Acral cutaneous lesions in the time of COVID-19. Journal of the European Academy of Dermatology and Venereology : JEADV. 2020;34(8):e346-e347. doi:10.1111/JDV.16533
20. PR M, KM J. Going viral: A brief history of Chilblain-like skin lesions (“COVID toes”) amidst the COVID-19 pandemic. Seminars in oncology. 2020;47(5):330-334. doi:10.1053/J.SEMINONCOL.2020.05.012
21. L LC, L D, H A, et al. Most chilblains observed during the COVID-19 outbreak occur in patients who are negative for COVID-19 on polymerase chain reaction and serology testing. The British journal of dermatology. 2020;183(5):866-874. doi:10.1111/BJD.19377
22. Piccolo V, Bassi A, Russo T, et al. Chilblain‐like lesions and COVID‐19: second wave, second outbreak. Journal of the European Academy of Dermatology and Venereology. 2021;35(5):e316-e318. doi:10.1111/JDV.17145
23. M B, A H. COVID toes: where do we stand with the current evidence? International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2021;102:53-55. doi:10.1016/J.IJID.2020.10.021
24. C L, J K, A V, et al. COVID-19 and outbreak of chilblains: are they related? Journal of the European Academy of Dermatology and Venereology : JEADV. 2020;34(12):e757-e758. doi:10.1111/JDV.16779
25. Mascellino MT, Timoteo F di, Angelis M de, Oliva A. Overview of the Main Anti-SARS-CoV-2 Vaccines: Mechanism of Action, Efficacy and Safety. Infection and Drug Resistance. 2021;14:3459. doi:10.2147/IDR.S315727
26. Do MH, Stewart CR, Harp J. Cutaneous Manifestations of COVID-19 in the Inpatient Setting. Dermatologic Clinics. 2021;39(4):521-532. doi:10.1016/J.DET.2021.05.011
27. N C, M S, M M, SP N, A C. Pernio-like skin lesions after the second dose of Pfizer-BioNTech COVID-19 vaccine. Journal of the European Academy of Dermatology and Venereology : JEADV. 2021;35(11). doi:10.1111/JDV.17500
28. Cappel MA, Cappel JA, Wetter DA. Pernio (Chilblains), SARS-CoV-2, and COVID Toes Unified Through Cutaneous and Systemic Mechanisms. Mayo Clinic Proceedings. 2021;96(4):989-1005. doi:10.1016/J.MAYOCP.2021.01.009
29. Verdecchia P, Cavallini C, Spanevello A, Angeli F. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. European Journal of Internal Medicine. 2020;76:14. doi:10.1016/J.EJIM.2020.04.037
30. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines — a new era in vaccinology. Nature reviews Drug discovery. 2018;17(4):261. doi:10.1038/NRD.2017.243
31. JR T, DL F. COVID-19 vaccines: modes of immune activation and future challenges. Nature reviews Immunology. 2021;21(4):195-197. doi:10.1038/S41577-021-00526-X
32. MA L, N L, C C, K N, ML R. Approach to Chilblains During the COVID-19 Pandemic [Formula: see text]. Journal of cutaneous medicine and surgery. 2020;24(5):504-517. doi:10.1177/1203475420937978
33. (10) (PDF) Cytokine Storm Response to COVID-19 Vaccinations. Accessed October 16, 2021. https://www.researchgate.net/publication/349257945_Cytokine_Storm_Response_to_COVID-19_Vaccinations
34. Mahase E. Covid-19: UK government asks regulator to assess Oxford vaccine as questions are raised over interim data. BMJ. 2020;371:m4670. doi:10.1136/BMJ.M4670
35. Ragab D, Eldin HS, Taeimah M, Khattab R, Salem R. The COVID-19 Cytokine Storm; What We Know So Far. Frontiers in Immunology. 2020;11. doi:10.3389/FIMMU.2020.01446
36. Lesort C, Kanitakis J, Donzier L, Jullien D. Chilblain-like lesions after BNT162b2 mRNA COVID-19 vaccine: a case report suggesting that ‘COVID toes’ are due to the immune reaction to SARS-CoV-2. Journal of the European Academy of Dermatology and Venereology. 2021;35(10):e630-e632. doi:10.1111/JDV.17451
37. GA H, M D, B L, et al. A case series of cutaneous COVID-19 vaccine reactions at Loma Linda University Department of Dermatology. JAAD case reports. 2021;16:53-57. doi:10.1016/J.JDCR.2021.07.038
38. Meara AS, Silkoski M, Quin K, Jarjour W. A Case of Chilblains-like Lesions Post SARS-CoV-2 Vaccine? The Journal of Rheumatology. 2021;(1):jrheum.210226. doi:10.3899/JRHEUM.210226
39. Lopez S, Vakharia P, Vandergriff T, Freeman EE, Vasquez R. Pernio after COVID-19 vaccination. British Journal of Dermatology. 2021;185(2):445-447. doi:10.1111/BJD.20404
40. Kha C, Itkin A. New-onset chilblains in close temporal association to mRNA-1273 vaccination. JAAD Case Reports. 2021;12:12-14. doi:10.1016/J.JDCR.2021.03.046
41. A B, I B, MT FF, C F. Perniosis: clinical and histopathological analysis. The American Journal of dermatopathology. 2010;32(1):19-23. doi:10.1097/DAD.0B013E3181AF1D24
42. Cribier B, Djeridi N, Peltre B, Grosshans E. A histologic and immunohistochemical study of chilblains. Journal of the American Academy of Dermatology. 2001;45(6):924-929. doi:10.1067/MJD.2001.117861
43. C GC, A C, G CH, et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. The British journal of dermatology. 2020;183(1):71-77. doi:10.1111/BJD.19163
44. Whitman PA, Crane JS. Pernio. Current Treatment Options in Cardiovascular Medicine. 2021;10(2):128-135. Accessed October 15, 2021. https://www.ncbi.nlm.nih.gov/books/NBK549842/
45. Temiz SA, Abdelmaksoud A, Dursun R, Vestita M. Acral chilblain-like lesions following inactivated SARS-CoV-2 vaccination. International Journal of Dermatology. 2021;60(9):1152-1153. doi:10.1111/IJD.15619
46. Piccolo V, Bassi A, Argenziano G, et al. Dermoscopy of chilblain-like lesions during the COVID-19 outbreak: A multicenter study on 10 patients. Journal of the American Academy of Dermatology. 2020;83(6):1749. doi:10.1016/J.JAAD.2020.07.058
47. Chilblain-Like Lesions in COVID-19: A Detailed Review. Accessed October 15, 2021. https://www.fortunejournals.com/articles/chilblainlike-lesions-in-covid19-a-detailed-review.html
48. M P, F M, MG K. Pharmacologic Treatment of Idiopathic Chilblains (Pernio): A Systematic Review. Journal of cutaneous medicine and surgery. 2021;25(5):530-542. doi:10.1177/1203475421995130
49. A A, DS P. Pernio (chilblains). Current treatment options in cardiovascular medicine. 2008;10(2):128-135. doi:10.1007/S11936-008-0014-0
50. M K, B I, S M, M A. Cutaneous and histopathological features of coronavirus disease 2019 in pediatrics: A review article. Dermatologic therapy. 2021;34(1). doi:10.1111/DTH.14554
51. Discepolo V, Catzola A, Pierri L, et al. Bilateral Chilblain-like Lesions of the Toes Characterized by Microvascular Remodeling in Adolescents During the COVID-19 Pandemic. JAMA Network Open. 2021;4(6):e2111369-e2111369. doi:10.1001/JAMANETWORKOPEN.2021.11369
52. Vano-Galvan S, Martorell A. Chilblains. CMAJ. 2012;184(1):67-67. doi:10.1503/CMAJ.110100
53. IH S, JH B, P S, AL LJ. Assessing the effectiveness of topical betamethasone to treat chronic chilblains: a randomised clinical trial in primary care. The British journal of general practice : the journal of the Royal College of General Practitioners. 2017;67(656):e187-e193. doi:10.3399/BJGP17X689413
54. Chou R, Dana T. Screening Adults for Bladder Cancer. Screening Adults for Bladder Cancer: Update of the 2004 Evidence Review for the US Preventive Services Task Force. Published online 2010. Accessed October 15, 2021. https://www.ncbi.nlm.nih.gov/books/NBK47510/
55. Khalid T, Arif Maan M, Shehzad K. Comparison of efficacy and safety of topical glyceryl trinitrate vs. oral nifedipine in idiopathic perniosis: results of a randomized clinical trial. Journal of Pakistan Association of Dermatologists. 2014;24(4):342-347.
56. Jain AK, K.R R, Margaankar M. A random comparative therapeutic trial of oral nifedipine v/s topical 5% minoxidil gel in patients of perniosis at a tertiary care center of North-western India. IP Indian Journal of Clinical and Experimental Dermatology. 2020;4(1):62-65. doi:10.18231/.2018.0014
57. Alkubaisi TA, Salih Hasan A. Treatment of Perniosis with Oral Nifedipine in Comparison with Topical 5% Minoxidil Solution in Iraqi Patients. Single Blind Comparative Study. Published online 2010. Accessed October 16, 2021. https://www.researchgate.net/publication/340129930
58. Diltiazem vs. nifedipine in chilblains: a clinical trial - PubMed. Accessed October 15, 2021. https://pubmed.ncbi.nlm.nih.gov/17642888/
59. IH S, JH B, P S, AL LJ. Nifedipine vs Placebo for Treatment of Chronic Chilblains: A Randomized Controlled Trial. Annals of family medicine. 2016;14(5):453-459. doi:10.1370/AFM.1966
60. Molecular mechanism of cGMP-mediated smooth muscle relaxation - PubMed. Accessed October 15, 2021. https://pubmed.ncbi.nlm.nih.gov/10911373/
61. Topical Nitroglycerine in Perniosis/Chilblains - PubMed. Accessed October 15, 2021. https://pubmed.ncbi.nlm.nih.gov/26380502/
62. Weingarten M, Abittan B, Rivera-Oyola R, Abittan AI, Weingarten M, Lebwohl M. Treatment of COVID-19 induced chilblains with topical nitroglycerin. International Journal of Dermatology. 2020;59(12):1522-1524. doi:10.1111/IJD.15253
63. Annamaraju P, Baradhi KM. Pentoxifylline. xPharm: The Comprehensive Pharmacology Reference. Published online August 22, 2021:1-18. Accessed October 15, 2021. https://www.ncbi.nlm.nih.gov/books/NBK559096/
64. Treatment of perniosis with oral pentoxyfylline in comparison with oral prednisolone plus topical clobetasol ointment in Iraqi patients - PubMed. Accessed October 15, 2021. https://pubmed.ncbi.nlm.nih.gov/19082229/
65. NK AS. Treatment of primary perniosis with oral pentoxifylline (a double-blind placebo-controlled randomized therapeutic trial). Dermatologic therapy. 2016;29(4):263-268. doi:10.1111/DTH.12350
66. Rich R, Fleisher T, Shearer W, Schroeder H, Frew A, Weyand C. Clinical Immunology - Principles and Practice. Published online 2008:1530.
67. Successful treatment of perniosis with hydroxychloroquine - PubMed. Accessed October 15, 2021. https://pubmed.ncbi.nlm.nih.gov/20941949/
68. RI F. Mechanism of action of hydroxychloroquine as an antirheumatic drug. Seminars in arthritis and rheumatism. 1993;23(2 Suppl 1):82-91. doi:10.1016/S0049-0172(10)80012-5
69. [Clinical observation on 136 cases of chilblains treated by acupuncture combined with massage] - PubMed. Accessed October 15, 2021. https://pubmed.ncbi.nlm.nih.gov/16312923/
70. LR B, HM ES, B E, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. The New England journal of medicine. 2021;384(5):403-416. doi:10.1056/NEJMOA2035389
71. Mazzatenta C, Piccolo V, Pace G, Romano I, Argenziano G, Bassi A. Purpuric lesions on the eyelids developed after BNT162b2 mRNA COVID‐19 vaccine: another piece of SARS‐CoV‐2 skin puzzle? Journal of the European Academy of Dermatology and Venereology. 2021;35(9):e543-e545. doi:10.1111/JDV.17340
72. M C, A D, MR V, et al. Transient cutaneous manifestations after administration of Pfizer-BioNTech COVID-19 Vaccine: an Italian single-centre case series. Journal of the European Academy of Dermatology and Venereology : JEADV. 2021;35(8):e483-e485. doi:10.1111/JDV.17268
73. M A, D H, A F, R B, E E. Persistent maculopapular rash after the first dose of Pfizer-BioNTech COVID-19 vaccine. Journal of the European Academy of Dermatology and Venereology : JEADV. 2021;35(7):e423-e425. doi:10.1111/JDV.17248
74. Morbilliform rash after administration of Pfizer-BioNTech COVID-19 mRNA vaccine - PubMed. Accessed November 6, 2021. https://pubmed.ncbi.nlm.nih.gov/33560802/
75. HJ P, JR M, NA B. Anaphylaxis After the Covid-19 Vaccine in a Patient With Cholinergic Urticaria. Military medicine. Published online April 14, 2021. doi:10.1093/MILMED/USAB138
76. DE M, E A, M R, et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases. Journal of the American Academy of Dermatology. 2021;85(1):46-55. doi:10.1016/J.JAAD.2021.03.092
77. JM BL, G SN, A MI, et al. Pityriasis rosea, COVID-19 and vaccination: new keys to understand an old acquaintance. Journal of the European Academy of Dermatology and Venereology : JEADV. 2021;35(8):e489-e491. doi:10.1111/JDV.17301
78. V P, C M, A B, et al. COVID vaccine-induced lichen planus on areas previously affected by vitiligo. Journal of the European Academy of Dermatology and Venereology : JEADV. Published online 2021. doi:10.1111/JDV.17687
79. B D, H M, M FB, K J, P de T. “Blue toes” following vaccination with the BNT162b2 mRNA COVID-19 vaccine. Journal of travel medicine. 2021;28(4). doi:10.1093/JTM/TAAB024
80. Piccolo V, Bassi A, Argenziano G, et al. BNT162b2 mRNA COVID-19 vaccine-induced chilblain-like lesions reinforces the hypothesis of their relationship with SARS-CoV-2. Journal of the European Academy of Dermatology and Venereology. 2021;35(8):e493-e494. doi:10.1111/JDV.17320
81. Pileri A, Guglielmo A, Raone B, Patrizi A. Chilblain lesions after COVID-19 mRNA vaccine. British Journal of Dermatology. 2021;185(1):e3-e3. doi:10.1111/BJD.20060
82. Revilla-Nebreda D, Roncero-Riesco M, Santos-Briz Á, Medina-Migueláñez M, Segurado-Tostón N, Román-Curto C. New-onset acral lesions on hands after administration of mRNA-1273 vaccine against SARS-CoV-2: clinical images and histopathological study of three cases. Journal of the European Academy of Dermatology and Venereology. 2021;35(11):e747-e749. doi:10.1111/JDV.17553
Published
2022-10-31
Issue
Section
Review
License
Copyright (c) 2022 Taha Gul Shaikh, Summaiyya Waseem, Syed Hassan Ahmed, Nashwa Abdul Qadir, Vincenzo Piccolo
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.
How to Cite
1.
Shaikh TG, Waseem S, Ahmed SH, Abdul Qadir N, Piccolo V. SARS-CoV-2 Vaccination and Chilblain-like Lesions: What Do We Know So Far?. Dermatol Pract Concept. 2022;12(4):e2022170. doi:10.5826/dpc.1204a170
Share
